The estimated Net Worth of Kathryn C Zoon is at least $2.69 Million dollars as of 4 June 2024. Kathryn Zoon owns over 10,000 units of Emergent Biosolutions Inc stock worth over $412,429 and over the last 8 years he sold EBS stock worth over $1,929,864. In addition, he makes $343,000 as Independent Director at Emergent Biosolutions Inc.
Kathryn has made over 19 trades of the Emergent Biosolutions Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of EBS stock worth $61,100 on 4 June 2024.
The largest trade he's ever made was selling 10,000 units of Emergent Biosolutions Inc stock on 4 June 2024 worth over $61,100. On average, Kathryn trades about 1,711 units every 89 days since 2016. As of 4 June 2024 he still owns at least 54,482 units of Emergent Biosolutions Inc stock.
You can see the complete history of Kathryn Zoon stock trades at the bottom of the page.
Dr. Kathryn C. Zoon serves as Independent Director of the Company.D., is Independent Director of the Company. Dr. Zoon is currently NIAID/NIH Scientist Emeritus, a position she has held since August 2016. From April 2016 to June 2016, she was Interim Director of the new NIH Office of Research Support and Compliance where she developed and established the new office and recruited key individuals to continue its future operations. She was also Chief of the Cytokine Biology Section in the Division of Intramural Research, National Institute of Allergy and Infectious Diseases ("NIAID"), NIH until July 2016, where she conducted research on the structure and function of human interferon alphas and developed a new cell therapy using IFNs and autologous monocytes which she is still collaborating with the National Cancer Institute ("NCI") to start a clinical trial for ovarian cancer. She was previously the Director of the Division of Intramural Research at NIAID from 2006- August 2015 and was the Deputy Director for Planning and Development of the Division of Intramural Research at NIAID, 2004-2006. Dr. Zoon served as the Principal Deputy Director of the Center for Cancer Research at the National Cancer Institute, 2003-2004. She served as the Director of the Center for Biologics Evaluation and Research ("CBER"), Food and Drug Administration ("FDA") (1992-2003), and has been a member of the NIH Scientific Directors from 1992 to 2015. Dr. Zoon was the Director of the Division of Cytokine Biology in CBER, 1988-1992, where she directed the research and review of cytokines, growth factors, and cellular products. She studied the production and purification of human interferon at NIH from 1975 to 1980 with Nobel Laureate Christian B. Anfinsen. She received her B.S. degree, cum laude, in chemistry from Rensselaer Polytechnic Institute and was granted a Ph.D. in biochemistry from the Johns Hopkins University.
As the Independent Director of Emergent Biosolutions Inc, the total compensation of Kathryn Zoon at Emergent Biosolutions Inc is $343,000. There are 16 executives at Emergent Biosolutions Inc getting paid more, with Robert Kramer having the highest compensation of $3,693,820.
Kathryn Zoon is 71, he's been the Independent Director of Emergent Biosolutions Inc since 2016. There are 4 older and 17 younger executives at Emergent Biosolutions Inc. The oldest executive at Emergent Biosolutions Inc is Louis Sullivan, 86, who is the Independent Director.
Kathryn's mailing address filed with the SEC is 400 Professional Dr #400, Gaithersburg, MD 20879, USA.
Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over $131,382,266 worth of Emergent Biosolutions Inc stock and bought 4,647 units worth $138,981 . The most active insiders traders include Seamus Mulligan, Fuad El Hibri und Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of $147,206. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth $61,100.
emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent
Emergent Biosolutions Inc executives and other stock owners filed with the SEC include: